热门资讯> 正文
辉瑞血友病B基因疗法Durveqtix获得欧盟委员会授权
2024-07-26 00:13
- 辉瑞(PFE) 0
- Informatica Inc.(NYSE) 0
- Benessere Capital Acquisition Corp Ordinary Shares - Class A(BENE) 0
- The European Commission has granted conditional marketing authorization to Pfizer's (NYSE:PFE) gene therapy Durveqtix (fidanacogene elaparvovec) as a one-time treatment for hemophilia B.
- Authorization was based on results of the phase 3 BENEGENE-2 trial that met its primary efficacy endpoint of non-inferiority to multiple factor IX infusions as well as a statistically significant decrease in annualized bleeding rate versus regular FIX infusions.
- The drug is already approved in the U.S. and Canada under the name Beqvez.
More on Pfizer
- Pfizer Opts To Move Forward With Once-Daily Danuglipron - Don't Hold Your Breath
- The Next Paxlovid
- Pfizer: Buy This Big Yielder On The Strong Pipeline
- Pfizer/ BioNTech win U.K. nod for JN.1-adjusted COVID-19 shot
- Pfizer/ Sangamo gene therapy for hemophilia A succeeds in late-stage trial
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
